Citius Oncology Files 8-K Report
Ticker: CTOR · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1851484
Sentiment: neutral
Topics: corporate-filing, company-name-change
TL;DR
CITIUS filed an 8-K on Feb 6, 2025, covering other events and financials. Formerly TenX Keane Acquisition.
AI Summary
On February 6, 2025, Citius Oncology, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as TenX Keane Acquisition until March 15, 2021, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing provides an update on Citius Oncology's corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- TenX Keane Acquisition (company) — Former company name
- February 6, 2025 (date) — Date of report
- March 15, 2021 (date) — Date of name change
- 001-41534 (other) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on "Other Events" and "Financial Statements and Exhibits" as of February 6, 2025.
What was Citius Oncology, Inc. formerly known as?
Citius Oncology, Inc. was formerly known as TenX Keane Acquisition.
When did the company change its name from TenX Keane Acquisition?
The company changed its name from TenX Keane Acquisition on March 15, 2021.
In which state is Citius Oncology, Inc. incorporated?
Citius Oncology, Inc. is incorporated in Delaware.
What is the principal executive office address of Citius Oncology, Inc.?
The principal executive office address is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-02-06 09:22:18
Filing Documents
- ea0230157-8k_citius.htm (8-K) — 23KB
- ea023015701ex99-1_citius.htm (EX-99.1) — 36KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- ex99-1_002.jpg (GRAPHIC) — 5KB
- 0001213900-25-010748.txt ( ) — 254KB
- ctor-20250206.xsd (EX-101.SCH) — 3KB
- ctor-20250206_lab.xml (EX-101.LAB) — 33KB
- ctor-20250206_pre.xml (EX-101.PRE) — 22KB
- ea0230157-8k_citius_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On February 6, 2025, Citius Oncology, Inc., along with its parent company, Citius Pharmaceuticals, Inc., issued a press release to announce that LYMPHIR (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System J-code by the Centers for Medicare & Medicaid Services. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated February 6, 2025. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: February 6, 2025 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2